Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension
- PMID: 37045971
- DOI: 10.1038/s41440-023-01272-4
Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension
Erratum in
-
Correction: Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension.Hypertens Res. 2023 Jul;46(7):1825. doi: 10.1038/s41440-023-01299-7. Hypertens Res. 2023. PMID: 37106046 No abstract available.
Abstract
Heart failure (HF) in the elderly is an increasingly large and complex problem in modern society. Notably, the cause of HF with preserved ejection fraction (HFpEF) is multifactorial and its pathophysiology is not fully understood. Among these, hypertension has emerged as a pivotal factor in the pathophysiology and therapeutic targets of HFpEF. Neuronal elements distributed throughout the cardiac autonomic nervous system, from the level of the central autonomic network including the insular cortex to the intrinsic cardiac nervous system, regulate the human cardiovascular system. Specifically, increased sympathetic nervous system activity due to sympatho-vagal imbalance is suggested to be associated the relationship between hypertension and HFpEF. While several new pharmacological therapies, such as sodium-glucose cotransporter 2 inhibitors, have been shown to be effective in HFpEF, neuromodulatory therapies of renal denervation and vagus nerve stimulation (VNS) have received recent attention. The current review explores the pathophysiology of the brain-heart axis that underlies the relationship between hypertension and HFpEF and the rationale for therapeutic neuromodulation of HFpEF by non-invasive transcutaneous VNS.
Keywords: Device therapy; HFpEF; Renal denervation; Treatment-resistant hypertension; Vagus nerve stimulation.
© 2023. The Author(s), under exclusive licence to The Japanese Society of Hypertension.
Similar articles
-
Autonomic neuromodulation for cardiomyopathy associated with metabolic syndrome - Prevention of precursors for heart failure with preserved ejection fraction.Hypertens Res. 2024 Dec;47(12):3318-3329. doi: 10.1038/s41440-024-01886-2. Epub 2024 Sep 11. Hypertens Res. 2024. PMID: 39261699 Review.
-
Cardiac diastolic and autonomic dysfunction are aggravated by central chemoreflex activation in heart failure with preserved ejection fraction rats.J Physiol. 2017 Apr 15;595(8):2479-2495. doi: 10.1113/JP273558. Epub 2017 Mar 19. J Physiol. 2017. PMID: 28181258 Free PMC article.
-
Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study.ESC Heart Fail. 2018 Feb;5(1):95-100. doi: 10.1002/ehf2.12241. Epub 2017 Dec 28. ESC Heart Fail. 2018. PMID: 29283224 Free PMC article. Clinical Trial.
-
Low-level transcutaneous vagus nerve stimulation attenuates cardiac remodelling in a rat model of heart failure with preserved ejection fraction.Exp Physiol. 2019 Jan;104(1):28-38. doi: 10.1113/EP087351. Epub 2018 Nov 29. Exp Physiol. 2019. PMID: 30398289 Free PMC article.
-
Advances in device-based treatment of heart failure with preserved ejection fraction: evidence from clinical trials.ESC Heart Fail. 2024 Feb;11(1):13-27. doi: 10.1002/ehf2.14562. Epub 2023 Nov 20. ESC Heart Fail. 2024. PMID: 37986663 Free PMC article. Review.
Cited by
-
Neural Circuits Underlying Reciprocal Cardiometabolic Crosstalk: 2023 Arthur C. Corcoran Memorial Lecture.Hypertension. 2024 Jun;81(6):1233-1243. doi: 10.1161/HYPERTENSIONAHA.124.22066. Epub 2024 Mar 27. Hypertension. 2024. PMID: 38533662 Free PMC article.
-
Microvascular rarefaction caused by the NOTCH signaling pathway is a key cause of TKI-apatinib-induced hypertension and cardiac damage.Front Pharmacol. 2024 Feb 9;15:1346905. doi: 10.3389/fphar.2024.1346905. eCollection 2024. Front Pharmacol. 2024. PMID: 38405666 Free PMC article. Review.
-
Home blood pressure measurement of hypertensive patients with cognitive impairment-Is it "environmental pressure"?Hypertens Res. 2024 Feb;47(2):573-575. doi: 10.1038/s41440-023-01526-1. Epub 2023 Nov 24. Hypertens Res. 2024. PMID: 38001168 No abstract available.
-
Cardioneuroablation Using Epicardial Pulsed Field Ablation for the Treatment of Atrial Fibrillation.J Cardiovasc Dev Dis. 2023 May 29;10(6):238. doi: 10.3390/jcdd10060238. J Cardiovasc Dev Dis. 2023. PMID: 37367403 Free PMC article. Review.
-
Autonomic neuromodulation for cardiomyopathy associated with metabolic syndrome - Prevention of precursors for heart failure with preserved ejection fraction.Hypertens Res. 2024 Dec;47(12):3318-3329. doi: 10.1038/s41440-024-01886-2. Epub 2024 Sep 11. Hypertens Res. 2024. PMID: 39261699 Review.
References
-
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61. - PubMed - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous